EN DE
Watch Pacific Edge Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pacific Edge Limited (PFGTF) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Pacific Edge Limited stock $0.08, price $0.13, that is 42.0% below the price, quality 34 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in New Zealand

PE Pacific Edge Limited logo Thin data Nov 10, 2026

Pacific Edge Limited

PFGTF · US
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Revenue last quarter 46% below a year ago.
Fair value $0.0783 · Strongly overvalued
Quality 34/100
Weak Growth (revenue 3y −16.0 %/yr in NZD)
Negative free cash flow
Trails peers (0/6)
Narrow moat 23/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch Pacific Edge Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.20 $0.0219 Fair Value $0.0783 Nov 2016 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.0219 – $1.20 · fair‑value band $0.0587 – $0.0979 · the $0.1349 price screens above the $0.0783 fair value. As of Nov 10, 2026.

Follow Pacific Edge in your weekly email

Every Wednesday you see whether Pacific Edge is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research.

Show moreShow less

The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer.

It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urological care; Cxbladder Triage Plus, a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a recurrent non-muscle invasive bladder cancer.

In addition, the company is developing products for bladder, gastric, colorectal and endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Stock analysis

Pacific Edge Limited (PFGTF) currently trades at $0.1349, while our estimate is $0.0783, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0587 (bear) to $0.0979 (bull), the price of $0.1349 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Pacific Edge Limited reported revenue of 11.6M NZD in FY2026 versus 11.4M NZD in FY2022, a compound +0.4%/yr. Reported net income was −36.1M NZD in FY2026.

Key figures

Market cap $168M Micro · P/S ratio 12.9 · EPS (TTM) $−0.0200 · Return on equity −195% · Return on assets (EBIT) −86.1% (5-year average) · Operating margin −274% · Revenue (TTM) 13.0M NZD · Revenue growth (YoY) −45.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 99% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −42%, PFGTF screens richer than that median.

Fair Value

Bear $0.0587 Fair Value $0.0783 Bull $0.0979
Price $0.1349 · Downside -42.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 16
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 37
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 58
Distance to the 52-week high, does not count
New shares 14
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−46.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.1%
Start year 2021 (pandemic). Over 10 years: +8.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,048.6% (2021) → −329.1% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

PFGTF screens overvalued: fair value 42% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Pacific Edge Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 149 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −42.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) −45.8% · Bottom 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 27.73× · Priciest 25%
P/S (12 months) 22.94× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥150.30 ¥165.32 +10% vs PFGTF
Illumina, Inc ILMN $214.91 $234.44 +9% vs PFGTF
IQVIA Holdings IQV $275.15 $299.58 +9% vs PFGTF
Thermo Fisher Scientific Inc TMO $718.20 $686.04 −4% vs PFGTF
Danaher Corporation DHR $236.11 $209.18 −11% vs PFGTF
IDEXX Laboratories, Inc IDXX $696.64 $496.48 −29% vs PFGTF
Mettler-Toledo International Inc MTD $1,751 $655.06 −63% vs PFGTF
Agilent Technologies, Inc A $177.88 $64.53 −64% vs PFGTF
Lonza Group LONN CHF 661.00 CHF 153.50 −77% vs PFGTF
Waters Corporation WAT $475.52 $91.26 −81% vs PFGTF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pacific Edge Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pacific Edge Limited Fair Value". https://www.fairvalue-calculator.com/stock/PFGTF

Frequently asked questions

Is Pacific Edge Limited (PFGTF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.0783 versus a price of $0.1349, about 42% lower (overvalued).
What is the fair value of PFGTF?
Our estimate for Pacific Edge Limited is $0.0783 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.1349.
What is the quality score of PFGTF?
Pacific Edge Limited has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pacific Edge Limited (PFGTF)?
Our calculated price target is the estimate of $0.0783 (as of Nov 10, 2026). Cautious scenario $0.0587, optimistic scenario $0.0979. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Pacific Edge Limited stock forecast for 2026?
Our estimate puts fair value at $0.0783, about 42% lower versus a price of $0.1349 (overvalued). Cautious scenario $0.0587, optimistic scenario $0.0979. The calculation is refreshed regularly with new filings.
What is the revenue of Pacific Edge Limited (PFGTF)?
Pacific Edge Limited reported trailing-twelve-month revenue of about 13.0M NZD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Pacific Edge Limited (PFGTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pacific Edge Limited it is $0.0783 per share (as of Nov 10, 2026), against a price of $0.1349.
Is Pacific Edge Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PFGTF trades above its calculated fair value: price $0.1349, fair value $0.0783, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PFGTF?
No. The price is what the market pays today ($0.1349); the fair value is what the company's own numbers justify ($0.0783). For Pacific Edge Limited the two are $0.0566 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pacific Edge Limited worth?
The market values Pacific Edge Limited at about $168M (market capitalisation, as of Nov 10, 2026). Per share that is $0.1349; our models calculate a fair value of $0.0783 per share.
What do the bullish and bearish scenarios say about PFGTF?
Our models span a range for Pacific Edge Limited: cautious scenario $0.0587, base $0.0783, optimistic $0.0979 per share (as of Nov 10, 2026, price $0.1349). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pacific Edge Limited (PFGTF)?
Balance-sheet figures for Pacific Edge Limited (as of Nov 10, 2026): return on equity −194.7%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is PFGTF from its 52-week high?
Pacific Edge Limited trades at $0.1349, about 42% below its 52-week high of $0.2327 and 99% above the low of $0.0678 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0783 is for.
Which stocks are comparable to Pacific Edge Limited?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pacific Edge Limited stock attractive at the current price?
The data as of Nov 10, 2026: price $0.1349, calculated fair value $0.0783 (−42%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Pacific Edge Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pacific Edge Limited (PFGTF)?
The closing price on Nov 6, 2026 was $0.1349. Our estimate is $0.0783, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pacific Edge Limited right now?
The price sits above even our optimistic bull case ($0.0979). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Pacific Edge Limited

How large is the market capitalisation of Pacific Edge Limited (PFGTF)?
The market capitalisation of Pacific Edge Limited is $168M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pacific Edge Limited (PFGTF)?
The price-to-sales ratio of Pacific Edge Limited is 12.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pacific Edge Limited (PFGTF)?
Earnings per share at Pacific Edge Limited are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pacific Edge Limited (PFGTF)?
The return on equity (ROE) of Pacific Edge Limited is −195% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pacific Edge Limited (PFGTF)?
On an EBIT basis the return on assets of Pacific Edge Limited is −86.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pacific Edge Limited (PFGTF)?
The operating margin of Pacific Edge Limited is −274% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pacific Edge Limited (PFGTF)?
Revenue at Pacific Edge Limited is growing −45.8% versus a year earlier (3y avg −16.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pacific Edge Limited (PFGTF) generate?
The free cash flow of Pacific Edge Limited is −32.4M NZD (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Pacific Edge Limited (PFGTF) hold?
Pacific Edge Limited holds more cash than debt, 6.6M NZD net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Pacific Edge Limited in the live analysis

One click puts Pacific Edge Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.